These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10328305)

  • 1. Synthetic oligosaccharides having various functional domains: potent and potentially safe heparin mimetics.
    Petitou M; Driguez PA; Duchaussoy P; Hérault JP; Lormeau JC; Herbert JM
    Bioorg Med Chem Lett; 1999 Apr; 9(8):1161-6. PubMed ID: 10328305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New synthetic heparin mimetics able to inhibit thrombin and factor Xa.
    Petitou M; Duchaussoy P; Driguez PA; Hérault JP; Lormeau JC; Herbert JM
    Bioorg Med Chem Lett; 1999 Apr; 9(8):1155-60. PubMed ID: 10328304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of new synthetic heparin mimetics.
    Hérault JP; Bernat A; Roye F; Michaux C; Schaeffer P; Bono F; Petitou M; Herbert JM
    Thromb Haemost; 2002 Jun; 87(6):985-9. PubMed ID: 12083506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [From heparin to synthetic antithrombotic oligosaccharides].
    Petitou M
    Bull Acad Natl Med; 2003; 187(1):47-56; discussion 56-7. PubMed ID: 14556453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4.
    Lane DA; Denton J; Flynn AM; Thunberg L; Lindahl U
    Biochem J; 1984 Mar; 218(3):725-32. PubMed ID: 6721831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational design of synthetic heparin analogues with tailor-made coagulation factor inhibitory activity.
    Grootenhuis PD; Westerduin P; Meuleman D; Petitou M; van Boeckel CA
    Nat Struct Biol; 1995 Sep; 2(9):736-9. PubMed ID: 7552742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a hexasaccharide sequence able to inhibit thrombin and suitable for 'polymerisation'.
    Duchaussoy P; Jaurand G; Driguez PA; Lederman I; Gourvenec F; Strassel JM; Sizun P; Petitou M; Herbert JM
    Carbohydr Res; 1999 Apr; 317(1-4):63-84. PubMed ID: 10466207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New antithrombotic oligosaccharides].
    Petitou M; Hérault JP; Bernat A; Driguez PA; Duchaussoy P; Lormeau JC; Herbert JM
    Ann Pharm Fr; 1999 May; 57(3):232-9. PubMed ID: 10427858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of thrombin-inhibiting heparin mimetics without side effects.
    Petitou M; Hérault JP; Bernat A; Driguez PA; Duchaussoy P; Lormeau JC; Herbert JM
    Nature; 1999 Apr; 398(6726):417-22. PubMed ID: 10201371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SR123781A, a synthetic heparin mimetic.
    Herbert JM; Hérault JP; Bernat A; Savi P; Schaeffer P; Driguez PA; Duchaussoy P; Petitou M
    Thromb Haemost; 2001 May; 85(5):852-60. PubMed ID: 11372679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide.
    Walenga JM; Jeske WP; Bara L; Samama MM; Fareed J
    Thromb Res; 1997 Apr; 86(1):1-36. PubMed ID: 9172284
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessment through chemical synthesis of the size of the heparin sequence involved in thrombin inhibition.
    Duchaussoy P; Jaurand G; Driguez PA; Lederman I; Ceccato ML; Gourvenec F; Strassel JM; Sizun P; Petitou M; Herbert JM
    Carbohydr Res; 1999 Apr; 317(1-4):85-99. PubMed ID: 10466208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro evaluation of synthetic heparin-like conjugates comprising different thrombin binding domains.
    Basten JE; Dreef-Tromp CM; de Wijs B; van Boeckel CA
    Bioorg Med Chem Lett; 1998 May; 8(10):1201-6. PubMed ID: 9871735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological properties of synthetic glycoconjugate mimics of heparin comprising different molecular spacers.
    Dreef-Tromp CM; Basten JE; Broekhoven MA; van Dinther TG; Petitou M; van Boeckel CA
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2081-6. PubMed ID: 9873490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of three heparin-binding serine proteinase inhibitors.
    Pratt CW; Whinna HC; Church FC
    J Biol Chem; 1992 May; 267(13):8795-801. PubMed ID: 1315739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new synthetic pentasaccharide with increased anti-factor Xa activity: possible role for anionic clusters in the interaction of heparin and antithrombin III.
    Petitou M; Lormeau JC; Choay J
    Semin Thromb Hemost; 1991; 17 Suppl 2():143-6. PubMed ID: 1948084
    [No Abstract]   [Full Text] [Related]  

  • 18. Synthesis of heparin partial structures and their binding activities to platelets.
    Koshida S; Suda Y; Sobel M; Ormsby J; Kusumoto S
    Bioorg Med Chem Lett; 1999 Nov; 9(21):3127-32. PubMed ID: 10560738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparinase I acts on a synthetic heparin pentasaccharide corresponding to the antithrombin III binding site.
    Yu G; LeBrun L; Gunay NS; Hoppensteadt D; Walenga JM; Fareed J; Linhardt RJ
    Thromb Res; 2000 Dec; 100(6):549-56. PubMed ID: 11152935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin.
    Olson ST; Swanson R; Raub-Segall E; Bedsted T; Sadri M; Petitou M; Hérault JP; Herbert JM; Björk I
    Thromb Haemost; 2004 Nov; 92(5):929-39. PubMed ID: 15543318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.